Two cohorts of rats, 240 with colon cancer and 150 controls, were assessed clinically and immunologically for their response to tumour and its management which was either by surgical excision alone or by surgical excision combined with either adjuvant chemotherapy or immunotherapy. The histology and invasion characteristics were observed for similarity with those of human lesions. Metastases were found in liver, lymph nodes, the peritoneum or lungs in 27% of animals during follow up. Significantly fewer adjuvant-treated rats had metastases than those receiving surgery alone (P < 0.05), and less total tumour weight was found in the adjuvant-treated rats at four (P <0.03) and six (P <: 0.001) weeks postoperatively. Animals in the adjuvant immunotherapy group survived longer than in either other group (P <0.001). The crude parameters of host response to tumour, body, spleen and mesenteric lymph node weight were recorded and the latter two indexed to body weight. The body weight of tumour and control rats increased significantly with time (P < 0.04). The spleen and mesenteric node indices were significantly (P < 0.04) greater in tumour than control rats and were varied by recurrent tumour growth and by the adjuvant treatment administered postoperatively.
Introduction
The prognosis for colorectal carcinoma has not improved in the past two decades (Cutler et al. 1975) . This is in spite of improved surgical techniques, advocated by Turnbull (1975) , and earlier diagnosis (McDermott et al. 1981) . Adjuvant chemotherapy following surgical resection has met with varied success (Gray 1980) and trials with adjuvant immunotherapy for intestinal cancer have been inconclusive (Moertel et al. 1975 ). However, levamisole, an immune stimulant, has been shown to have beneficial effects in the treatment of lung and breast cancer and may confer some advantage in colonic tumour management (Amery 1978) . The results of Taylor et al. (1979) suggest that the route and timing of drug administration may be critical.
Preliminary studies of adjuvant therapies in an animal model may advantageously establish appropriate treatment protocols and enable assessment of the effect of drugs on the immune response, postoperative recovery and tumour growth. These parameters were studied in a rat model of colon carcinoma treated by surgery alone or surgery plus an adjuvant -either 5-fluorouracil (5-FU) or levamisole. The practicability of using these therapies in the model, similarities with the human circumstance, and the clinical and immune behaviour of the tumour host were assessed .
.Materials and methods Animals and animal treatments weeks of age (Nigro et al. 1973) . One hundred and fifty rats given saline alone over the same period acted as controls.
Twenty-one weeks after the commencement of DMH injections, rats with bowel tumours had these excised under gaseous anaesthesia. Multiple tumours were excised in one bowel segment if they were close in proximity or individually if they were quite separate. Bowel continuity was restored by an end-to-end anastomosis and the abdomen closed." A dose of 0.4 mg gentamicin was given intraperitoneally. The excised tumour was washed in saline and a 0.5 mm piece implanted subcutaneously in the left axilla before the rats were allowed to recover. Rats without neoplasms were excluded from further study. Control rats were managed similarly but had a small segment of normal bowel excised and tumour was not implanted in the axilla.
Tumour and control animals were allocated to three treatment regimens. These were surgery alone, surgery plus chemotherapy (5-FU 15 mg/kg given intravenously on the two days following operation), and surgery plus adjuvant immunotherapy (Ievamisole 5 mg/kg given intravenously on the two days following operation and weekly thereafter until sacrifice). Twelve animals from each group were sacrificed and examined at two-weekly intervals.
Survival
Of the operative survivors who had had tumours, 44 were observed until their death: II in the surgery-alone group, 18 in the adjuvant chemotherapy group and 15 in the adjuvant immunotherapy group.
Tumour/host response Tumour growth following 'curative' surgery and the host's response to tumour and treatment were assessed gravimetrically. The former was inferred from the total weight (grams) of tumour found, and the latter from body, spleen and mesenteric lymph node weights (grams) of each animal. Spleens and lymph nodes with macroscopic tumour were excluded from this analysis. Potential fluctuations in organ weight due to variations in animal body weight were minimized by indexing each of the measured parameters to body weight. Hence tumour, spleen and mesenteric lymph node indices for each animal were expressed as tumour index = weight of total tumour/body weight; spleen index = spleen weight/body weight; and mesenteric node index = mesenteric lymph node weight/body weight.
The total tumour weight was the sum of the weights of new bowel tumours removed from the entire opened intestine, the tumour implant dissected from the axilla, and metastatic deposits. Metastatic neoplasms could not be accurately weighed as the interface between normal and tumour tissue could not be defined. Therefore rats with metastases were allocated either + I (0.007 g equivalent to a 4 mm diameter tumour) if one liver nodule or one lymph node was involved, or +2 (0.14 g equivalent to an 8 mm tumour) for two nodules or nodes. Metastases were confirmed histologically.
Tumour histology
The type, degree of differentiation and depth of invasion of bowel tumours were established by histological examination of paraffin sections stained with haematoxylin and eosin.
Statistical methods of comparison
The time of observation, body weight, spleen and mesenteric lymph node and tumour index for rats within each treatment group were compared by analysis of variance using the 'ON EWAY' and 'ANOYA' subprogrammes of the Statistical Package for the Social Sciences. Each data recording represents the mean and standard deviation of the results from 12 animals. Survival was compared by a logrank chi-squared test and by the method of Metcalf (1975) in which the percent survival was plotted on the logarithmic axis of semi-log paper versus time on the x axis for each treatment group. The regressions of these three curves were then cornnared bv an analvsis of variance.
Results

Animals
Two hundred and eighteen (90%) of the total 240 rats were found to have bowel neoplasms at operation, while no tumours were seen in the 150 control rats. Sixty-five percent of rats had single bowel tumours, while 35% had more than one bowel neoplasm. One hundred and ninety-seven tumour and 126 saline control rats survived surgery. The operative mortality was 12%.
Tumours
Histological examination of a random sample of 107 tumours excised at operation demonstrated that 67% were well-differentiated, 22% moderately differentiated and II % poorly differentiated adenocarcinomas. Four percent of tumours were confined to the mucosa (equivalent to Dukes A human lesions). Invasion through the lamina propria occurred in 26% (equivalent to Dukes B lesions), and there was evidence of extensive invasion of the bowel wall in 70% (equivalent to B 2/C lesions). At primary resection only 4% of tumour rats had abdominal metastases. These were usually found in association with lesions that were extensively invading the bowel wall.
Eighty-nine percent of tumours found at the time of surgery were in the large bowel and II % were in the small intestine. The treatment protocols were found to completely prevent tumour metastases or subsequent new tumour development in 10% of rats, one of which was in the surgery alone group and 7 of which were in each of the adjuvant therapy groups. Twenty-seven percent of rats developed metastatic disease as distinct from new tumour, the adjuvant therapy groups again being advantaged (Table I) . Forty-five percent of metastatic deposits were in the liver, 46% in the mesenteric lymph nodes, 6% in the lungs and 3% in the kidneys.
Tumour index ( Figure I) The tumour index for each treatment group was not different at two or eight weeks, but at four and six weeks both the adjuvant therapies resulted in rats having significantly less tumour (a smaller index) than those treated by surgery alone (P < 0.01). (Table 2) There was significant body weight gain in both the tumour and control rats during the time of study (P < 0.002), and therapy did not influence this. Tumour rats tended to be lighter than their controls, but not significantly so.
Body weight
Spleen index (Figure 2 ) Spleens from tumour rats treated by surgery alone or surgery plus immunotherapy were significantly heavier (a greater spleen index) than those of control rats at each observation Figure 2 . Spleen index in the three treatment groups for tumour and control rats. The index ill tumour rats was significantly greater than in control rats receiving surgery alone and surgery plus levamisole between 2 and 8 weeks (P < 0.001) and surgery plus 5-FU at 6 and 8 weeks (P < 0.05) interval (P < 0.00I). This was not so for tumour animals receivmg surgery plus chemotherapy at two and four weeks, but by six and eight weeks their spleen indices were significantly greater than those of their equivalent controls (P < 0.05). Among the tumour animals, those treated with adjuvant chemotherapy had smaller spleen indices at two and eight weeks (P < 0.04) than those of rats receivingsurgery alone. The spleen indices of control rats in the surgery plus chemotherapy group were consistently greater than those of the other control animals (P <0.01).
Mesenteric lymph node index ( Figure 3 ) The mesenteric nodes of tumour rats were significantly heavier (larger indices) than those of control rats (P < 0.04). This difference was not statistically significant at two weeks in the surgery-alone group nor at two and four weeks in the surgery plus adjuvant immunotherapy treatment group. Among the tumour animals, those receiving adjuvant therapies had Figure 3 . Mesenteric lymph node index for tumour and control rats. The tumour rat index was significantly greater than controls (P < 0.04) significantly smaller mesenteric node indices at four weeks than those who had had only surgical excision of their neoplasm (P < 0.04). The reverse was true between adjuvant immunotherapy and surgery at eight weeks (P < 0.004). The control rats did not have these differences between treatment groups, except between adjuvant immunotherapy and adjuvant chemotherapy at six weeks (P < 0.02).
Survival (Figures 4 and 5)
There was no significant difference in the number of rats surviving to 12 weeks in the three treatment groups as assessed by an overall logrank chi-squared test (Figure 4 ). However, examination of the rate of decay in the survival curves for each treatment (Metcalf 1975) showed that the death rate in rats treated by surgery plus levamisole was significantly lower than in those receiving surgery alone or surgery plus adjuvant 5-FU (P < 0.001). Fifty percent of animals were dead after 6. 09, 6.46, 9.48 weeks in the surgery-alone, surgery plus adjuvant chemotherapy and surgery plus adjuvant immunotherapy groups respectively ( Figure 5 ).
Splenic histology
Extramedullary haemopoiesis was seen in every spleen including those of control rats. This was least in the spleens of the control surgery-alone group and marked in 5-FU treated rats when abundant megakaryocytes were also found. These changes were most obvious at two weeks and had receded by eight weeks in control rats. Haemopoiesis persisted in' tumour animals. The mesenteric lymph nodes and spleens also appeared non-specifically immunologically reactive.
Discussion
In the past the validity of cancer therapy in animal models has been questioned ' (Bartlett et 01. 1976 ). This particular model of colon cancer, although not a spontaneously-arising neoplasm, does have features to recommend it for use in the preliminary evaluation of the clinical and immunological effects of therapeutic trials. The tumour produced by 1,2dimethylhydrazine is not unlike that found in man where numerous endogenous and dietary carcinogens have been postulated. Morphologically it is similar; it can be histologically graded from well to poorly differentiated and has been shown to be capable of maturing from polyp to frank neoplasm (Carachi et 01. 1980) , but there is disagreement concerning this latter progression (Pozharisski 1975) . The tumour invasiveness noted in this study at the time of primary resection had some similarity to that seen in man but there were fewer lesions equivalent to Dukes stage A and D (Chapuis et 01. 1980 , McDermott et al. 1981 . The proportions of stage A (4%), B (26%) and B 2/C (70%) type tumours concurred with those noted in DMH-treated Sprague-Dawley rats (Carachi et 01. 1980) . The cancer was more aggressive than the human equivalent, for all tumour animals died of their disease regardless of tumour stage at surgical resection. This is unlike human tumours in which patients with stage A lesions can expect to live almost as long as their nontumour counterparts of the same age (Faulkner & House 1981) . This difference probably resides in the ability of DMH to continue producing new lesions after its application has stopped. In these experiments there were many more metachronous tumours than in man, as 90% of animals developed more than one neoplasm while only 2% of human individuals (Lavin et 01. 1980) can be expected to have a second primary carcinoma found at their first bowel resection. In the prevention of new and metastatic tumours, treatment by either adjuvant was effective in enabling more animals to remain tumour free. This is in accord with other studies. Topical intrarectal 5-FU has been shown to lower significantly the incidence of colon carcinoma in this rat model (Narisawa et 01. 1980) , while in man adjuvant 5-FU may be beneficial according to the responder status of the patient (Mitchell & DeConti 1970 , Payne et 01. 1981 but usually is associated with little improvement in patient survival (Grage & Moss 1981 , Lawrence 1979 , Gray 1980 . Adjuvant levamisole combined with other immunological therapies resulted in improved cancer control in other rat studies (Bansal et 01. 19780, b) and correction of immune deficiency in aged mice (Bruley-Rosset et 01. 1980) . That animals treated with levamisole had a statistically significantly improved survival is encouraging and supports the optimistic results from some human trials in leukaemia (Pavlovsky et 01. 1981) , breast, lung and colon cancer (Amery 1978) . However, more recently the advantages of levamisole therapy in the treatment of carcinoma of the lung have been questioned (Davis et 01. 1982) .
The spleen enlargement in control rats given 5-FU was explained histologically. The extramedulIary haemopoiesis with the presence of megakaryocytes in this study has been reported in mice recovering from the cytotoxic effects of treatment with high-dose 5-FU (Radley et 01. 1980) . Thus the histological appearance of spleens two weeks after 5-FU administration in this study is in accord with previously reported work and accounts for some of the splenic weight increase seen in the group of animals receiving this adjuvant therapy. The haemopoiesis seen in the spleens of the other tumour rat groups might .suggest that the carcinogen was marrow toxic and influenced spleen size. However, spleen and lymph node enlargement are a feature of the immune response to tumour growth in animal models (Edwards & Lee 1977 , Jones et 01. 1978 , Mitcheson et 01. 1980 , and the regional lymph node may act primarily to establish allograft or tumour immunity (Futrell & Myers 1972) . In this animal model the mesenteric lymph nodes and spleen contained lymphocytes cytotoxic to tumour cells (House 1981) . Primary tumour excision resulted in decreased spleen size (spleen index) until the sixth postoperative week when the index increased.
Similarly, mesenteric node index increased with time. This was most marked in the surgeryalone animals in the fourth postoperative week when the index increased and was shifted to a later time by adjuvant treatment. These increased indices coincided with increases in the tumour index of the corresponding animal group. The control rat indices moved in the opposite direction and decreased with time. These contrasting changes between tumour and control animals and between treatment groups suggest that tumour rats were responding immunologically to the increasing tumour burden and not to their treatment or to the carcinogen that had long ceased to be given. Histologically both the spleen and lymph nodes were immunologically active, but this did not indicate whether their cellular components were Iymphocytotoxic or suppressor in function. The time for the spleen and lymph node lymphocytes of these rats to change from Iymphocytotoxic to predominantly suppressor in function as recorded in other animal models (Jessup et al. 1982 , Argyris 1981 , Mitcheson et al. 1980 ) must be short, for most animals had died of their tumour by the twelfth postoperative week. In mice (Nofchissey et al. 1980 ) and rats (Meyer et al. 1980) suppressor cell function can be reduced and survival prolonged by splenectomy. However, rats with DMH-induced colon cancer treated this way do not enjoy such prolonged survival (Bansal et al. 1978b) . The spleen and lymph node changes seen in this study are immunologically and tumour related, but their functional significance is not clear from this or other studies cited in the literature. However, within the first eight postoperative weeks lymphocytes from these organs were immunologically competent (Maley 1983) .
A small piece of tumour was implanted into the axilla of each of the tumour rats. This implant was intended to simulate a metastasis that could be readily observed but seldom grew arid probably caused the animals to be further immunized against their tumour. Previously reported results of in vitro leukocyte migration inhibition showed the surgeryalone rats to be tumour-immune by eight weeks (Maley 1983 ). This immunity may explain the tumour index observation in the eighth postoperative week when the surgeryalone animals were found to have an index that had fallen to levels similar to those of the adjuvant-treated rats. Others have found that surgical excision of the tumour (Bansal et al. 1979) or surgical excision and immunization with irradiated tumour cells (Steele et al. 1982) inhibited further tumour growth and metastasis. In the present study the tumour implant did not control further tumour growth, but if it did exert an influence this was overridden by the adjuvant therapies which did suppress new and metastatic tumour and give a survival advantage.
